Zund Santiago, Califano Inés, Carrizo Fernando, Quildrian Sergio
Department of Head and Neck Surgery, Instituto de Oncología Ángel H. Roffo (IOAHR), University of Buenos Aires, Buenos Aires C1417DTB, CABA, Argentina.
https://orcid.org/0000-0001-6357-6136.
Ecancermedicalscience. 2025 Apr 25;19:1902. doi: 10.3332/ecancer.2025.1902. eCollection 2025.
A limited number of case reports have investigated the role of tyrosine kinase inhibitors as neoadjuvant therapy in locally invasive poorly differentiated thyroid cancer (PDTC).
A 69-year-old female patient presented with a large mass in the right thyroid lobe measuring 10 × 8 cm. A computed tomography scan showed a mass with no cleavage plane between the tumour and both the laryngotracheal and esophageal right lateral wall. A core needle biopsy was performed and confirmed PDTC. The case was considered unresectable. After a trial of neoadjuvant lenvatinib was administered, a partial response of 50% was achieved and surgery could be performed with favourable surgical outcomes. The patient did not resume lenvatinib after surgery, as no evidence of structural disease was found. At publication, she remains free of structural disease with an incomplete biochemical response.
Neadjuvant lenvatinib can be a therapeutic option to reduce primary tumour extent, in order to perform surgery and achieve better outcomes. However, this requires a highly selected patient group. Neoadjuvant-targeted therapy holds significant promise and warrants further investigation.
少数病例报告研究了酪氨酸激酶抑制剂作为新辅助治疗在局部浸润性低分化甲状腺癌（PDTC）中的作用。
一名69岁女性患者，右侧甲状腺叶有一个10×8 cm的大肿块。计算机断层扫描显示肿块与喉气管和食管右侧壁之间无分界平面。进行了粗针活检，确诊为PDTC。该病例被认为无法切除。在试用新辅助乐伐替尼后，获得了50%的部分缓解，并且可以进行手术，手术效果良好。术后患者未恢复使用乐伐替尼，因为未发现结构疾病的证据。在发表本文时，她仍无结构疾病，但生化反应不完全。
新辅助乐伐替尼可以作为一种治疗选择，以减少原发肿瘤范围，从而进行手术并取得更好的效果。然而，这需要高度选择的患者群体。新辅助靶向治疗具有重大前景，值得进一步研究。
